OIs

Related by string. OI * * Libor OIS spread . Libor OIS spreads . Oi Va Voi . LIBOR OIS spread . LIBOR OIS . OIS EMR . dollar Libor OIS . Libor OIS . Aussie Aussie Oi . Corporation dba OI . MEGA OIS Optical Image . NYSE OI . MEGA OIS . No Ka Oi . NYSE OIS . Mega OIS . symbol OIS . OI Plastics . OI manufactures . Franà § ois . OI Change . Oi Oi Oi . Oi oi oi . Oi Oi . oi oi . OIS EyeScan . - -Aussie Aussie oi *

Related by context. All words. (Click for frequent words.) 61 falciparum malaria 60 virus HBV 60 combination antiretroviral therapy 60 P. falciparum malaria 60 bacteraemia 60 coinfections 60 Acquired Immunodeficiency Syndrome 59 C. trachomatis 59 coinfection 59 myeloproliferative neoplasms 59 Pneumocystis carinii pneumonia 59 chlamydial infections 59 S.aureus 59 Enterobacteriaceae 59 Asymptomatic 59 haematological malignancies 59 acute respiratory tract infections 59 HBeAg + 59 Thiovir 59 HIV coinfected 58 abacavir Ziagen 58 HepC 58 Opportunistic infections 58 enterococcal 58 Candida infection 58 NRTI resistance 58 atrophic gastritis 58 Lipodystrophy 58 hepatorenal syndrome 58 falciparum 58 fluconazole resistant 58 Sexually Transmitted Infections STIs 57 BARACLUDE ® 57 cryptococcal meningitis 57 co trimoxazole 57 gastric adenocarcinoma 57 Bronchiectasis 57 Plasmodium falciparum malaria 57 Staphylococcus aureus infections 57 pneumococcal infection 57 serotype #A 57 HIV HCV coinfected 57 N. gonorrhoeae 57 receiving antiretroviral therapy 57 slow progressors 57 CMV infection 57 NNRTI resistance 57 serologic testing 57 HIV seropositive 57 acute rheumatic fever 57 relapsed MM 57 fluoroquinolone resistance 57 latent tuberculosis infection 57 neutropenic patients 57 polymicrobial 57 TB MDR TB 57 invasive aspergillosis 57 haemorrhagic fevers 57 carbapenem resistant 57 coinfected 57 HBeAg negative 57 TTR amyloidosis 57 hemorrhagic cystitis 57 Hepatitis C Virus 56 Retreatment 56 Multi Drug Resistant 56 gonococcal 56 recurrent genital herpes 56 dengue haemorrhagic fever DHF 56 NOMID 56 liver transplantations 56 antiretroviral naïve 56 malaria endemic regions 56 HIB vaccine 56 S. aureus isolates 56 candidemia 56 Clostridium difficile infections 56 susceptible isolates 56 uncomplicated malaria 56 seropositivity 56 BSIs 56 genital herpes infections 56 Neisseria gonorrhoeae 56 HIVAN 56 Virus HIV 56 Falciparum 56 Protease Inhibitors 56 methicillin susceptible Staphylococcus aureus 56 VZV 56 MDR tuberculosis 56 rectal gonorrhea 56 dapsone 56 NNRTIs 56 varicella infection 56 dengue haemorrhagic fever 56 cerebrovascular accidents 56 HCV infections 56 HCV Genotype 56 rotavirus diarrhea 56 histologic subtype 56 Trichomonas vaginalis 55 receiving VELCADE 55 nonmelanoma skin cancers 55 ASCUS 55 postexposure prophylaxis 55 Febrile neutropenia 55 oesophageal adenocarcinoma 55 Extensively drug 55 perinatal transmission 55 asymptomatic carriers 55 Combination antiretroviral therapy 55 Multidrug resistant 55 dengue hemorrhagic fever DHF 55 trastuzumab Herceptin ® 55 vancomycin resistant Staphylococcus aureus 55 Anti Retroviral Treatment 55 potent antiretroviral therapy 55 Hepatitis B Virus 55 AZT zidovudine Retrovir 55 tipranavir r 55 streptococcal 55 methicillin resistant S. aureus 55 recurrent venous thromboembolism 55 Bacteremia 55 Exacerbations 55 multidrug resistant strains 55 BRAF V#E 55 tuberculin skin testing 55 Abacavir 55 HbF 55 mycobacterial infections 55 ritonavir boosted 55 REYATAZ ® 55 MRSA isolates 55 liposomal amphotericin B 55 opportunistic infections 55 coinfected patients 55 ALT flares 55 hypersensitivity reactions eg anaphylaxis 55 tipranavir 55 linezolid resistant 55 multidrug resistant MDR 55 Antiviral Therapy 55 Natalizumab 55 de novo AML 55 rotaviruses 55 inactivated poliovirus vaccine 55 pneumococci 55 cryptococcus 54 Methicillin resistant S. aureus 54 immunocompetent 54 Artesunate 54 ATTR CM 54 enteroviral 54 Pegylated Interferon 54 Escherichia coli Klebsiella pneumoniae 54 immunocompromised patients 54 Renal impairment 54 zidovudine AZT 54 reproductive tract infections 54 IPAH 54 thrombocytopenic 54 respiratory viral infections 54 DISEASES 54 Chronic Prostatitis 54 MDRTB 54 cytomegalovirus infection 54 quadrivalent 54 lichen planus 54 Dengue Virus 54 liver transplant recipients 54 Japanese Encephalitis JE 54 N. meningitidis 54 nonbacterial 54 hepatitis C HCV 54 placental malaria 54 Progressive Multifocal Leukoencephalopathy 54 chlamydial infection 54 vWD 54 chronic HBV 54 SLNB 54 systemic fungal infections 54 latent tuberculosis TB 54 C. diff infection 54 genital ulcer 54 Kaposi Sarcoma 54 Klebsiella 54 S aureus 54 cART 54 invasive fungal infections 54 cSSSIs 54 superinfection 54 cells μL 54 Adenomas 54 PTLD 54 prostate cancer CaP 54 bacterium Neisseria meningitidis 54 amisulpride 54 RISPERDAL ® 54 Acute myeloid leukemia 54 vivax 54 neurological manifestations 54 HIV uninfected 54 acid suppressive medication 54 leukemia ALL 54 essential thrombocythemia ET 54 Juvenile Idiopathic Arthritis 54 Malignant Melanoma 54 serologically 54 bacterial vaginosis BV 54 Vancomycin Resistant 54 immunodeficient 54 Subtype 54 Simian Immunodeficiency Virus 54 humoral responses 54 transthyretin amyloidosis 54 Adefovir 54 TMP SMX 54 virus HCV 54 multiresistant 54 Cytomegalovirus CMV 54 chronic HCV infection 54 ESBLs 54 hematologic toxicity 54 quinolone resistant 54 parasitaemia 54 gonorrhoeae 54 haemorrhagic 54 basal cell carcinoma BCC 53 fluoroquinolone resistant 53 intravenous bisphosphonates 53 Antiretroviral ARV 53 Hib meningitis 53 e antigen HBeAg 53 acquired immunodeficiency syndrome 53 Staphylococcus aureus MRSA 53 CCHF virus 53 HSV1 53 external genital lesions 53 enteroviruses 53 de aths 53 Systemic Lupus Erythematosus SLE 53 HEPATITIS 53 SGPT 53 encephalomyelitis 53 chlamydial 53 SSPE 53 P aeruginosa 53 HIV seroprevalence 53 bacterium Mycobacterium tuberculosis 53 C. difficile toxins 53 immunosuppressed patients 53 Klebsiella pneumoniae 53 Latent TB 53 Sexually Transmitted Infections STI 53 invasive fungal infection 53 subcutaneous immunoglobulin 53 enteric fever 53 pneumococcal pneumonia 53 null responder 53 HCV genotypes 53 Chronic lymphocytic leukemia 53 HBeAg 53 resistant S. aureus 53 nucleotide analog 53 Diarrheal 53 germline mutations 53 Integrase Inhibitor 53 Multidrug Resistant 53 APTIVUS r 53 HER2 overexpression 53 viral subtypes 53 EBV infection 53 parasitemia 53 Haemophilus Influenzae 53 influenzae 53 flutamide 53 chronic Hepatitis B 53 relapsed ALL 53 Meningococcemia 53 Recurrences 53 pH#N# 53 Angioedema 53 trimethoprim sulfamethoxazole 53 Amodiaquine 53 C difficile infection 53 CCR5 receptor antagonist 53 LCMV infection 53 lupus anticoagulant 53 T. pallidum 53 Staphyloccus aureus 53 Hepatitis B virus HBV 53 KRAS mutant tumors 53 Bacterial Vaginosis 53 Sezary syndrome 53 Ribavirin causes 53 FluCAM arm 53 clade B 53 Vector borne diseases 53 simplex virus 53 chemoprophylaxis 53 pharmacologic intervention 53 cervicitis 53 penicillin resistant Streptococcus 53 invasive candidiasis 53 cirrhosis liver failure 53 CRBSI 53 gonococcal infection 53 etiologic agent 53 plasmodium falciparum 53 Respiratory Syncytial Virus RSV 53 severe rotavirus gastroenteritis 53 Bloodstream infections 53 HBeAg positive patients 53 osteosarcomas 53 Idiopathic Pulmonary Fibrosis 53 Folate deficiency 53 neuropsychiatric symptoms 53 Protease Inhibitor 53 Myelodysplastic Syndrome MDS 53 TEAEs 53 chronic HBV infection 53 initiating antiretroviral therapy 53 ocular toxicity 53 leiomyomas 53 urethritis 53 AZT 3TC 53 cervical HPV 53 Leukemias 53 Herpes Simplex 53 immune reconstitution syndrome 53 genital ulcers 53 Babesiosis 53 CMV retinitis 53 acute diarrheal disease 53 Ischemic heart 53 pyrimethamine 53 ano genital warts 53 Decitabine 53 Acquired Immuno Deficiency Syndrome 53 Enterococcus faecium 53 serologic tests 53 Kala Azar 53 neoplasias 53 endophthalmitis 53 Salmonella typhi 53 VACCINATION 53 Hepatitis B virus 53 Retroviral 53 Nilotinib 53 Squamous 53 vancomycin resistant 53 HBV infections 53 macrolide resistant 53 Tuberculosis TB 53 Pneumococcal Vaccine 53 vivax malaria 53 Invasive pneumococcal disease 53 filarial 52 myelodysplastic myeloproliferative diseases 52 haemophilus influenzae type 52 nonnucleoside reverse transcriptase inhibitors 52 nucleoside analogue 52 dermatophytes 52 vaccinees 52 HAART initiation 52 seroconverted 52 pneumocystis pneumonia 52 treatment naive genotype 52 ß blockers 52 rilpivirine 52 Gag polymorphisms 52 Lymphocytic 52 diarrhea dysentery 52 LV dysfunction 52 CA MRSA infections 52 Viral infections 52 Acute Renal Failure 52 CCR5 tropic 52 Chlamydia trachomatis 52 S. aureus infections 52 multidrug resistant MDR TB 52 Pelvic Inflammatory Disease 52 pneumococcal serotypes 52 Nonalcoholic fatty liver 52 CIN3 52 candidiasis 52 stavudine 52 streptococcal infections 52 Tigecycline 52 antiretroviral therapy ART 52 Chlamydia trachomatis infection 52 transgenic rats 52 human metapneumovirus 52 anti tubercular 52 Anti Retro Viral 52 gonococcal infections 52 R5 tropic 52 nosocomial infection 52 Hemorrhagic 52 virologic responses 52 C. difficile infections 52 nucleoside analog 52 neurologic complications 52 multidrug resistant tuberculosis MDR 52 P. ovale 52 microbial keratitis 52 anti retroviral therapies 52 hematologic abnormalities 52 Neisseria meningitides 52 sulfamethoxazole 52 Nosocomial 52 genotypic resistance 52 Mycoplasma pneumoniae 52 Herpes zoster 52 venous blood clots 52 Associated Diarrhea 52 cytomegalovirus retinitis 52 receiving VICTRELIS 52 C.difficile 52 Enterococci 52 Aspergillosis 52 Anaplasma 52 b Hib 52 varicella zoster virus VZV 52 indinavir Crixivan 52 interferon ribavirin 52 pulmonary hypertension PH 52 cotrimoxazole 52 hypervirulent strain 52 Kala azar 52 herpesviruses 52 lymphocyte count 52 postoperative infections 52 piperacillin tazobactam 52 ChimeriVax JE 52 Highly Active 52 anagrelide 52 K#N 52 virologic failure 52 tigecycline 52 Didanosine 52 d4T stavudine Zerit 52 bacterial sepsis 52 diabetic kidney 52 post transplant lymphoproliferative 52 Norovirus infection 52 Sexually Transmitted Infection 52 Nitazoxanide 52 Glioblastoma Multiforme 52 haemorrhagic dengue 52 Plasmodium ovale 52 NS#/#A protease 52 Epstein Barr virus EBV 52 pneumoniae 52 hepatitis B infection 52 hydroxychloroquine 52 oropharyngeal candidiasis OPC 52 HIV1 52 sleeping sickness trypanosomiasis 52 diarrheal infections 52 antibody titer 52 Valopicitabine 52 IPTp 52 poor metabolizers 52 Vicriviroc 52 nucleoside analogues 52 basal cell nevus syndrome 52 viraemia 52 sulphadoxine pyrimethamine 52 quinolone 52 hepatitis C genotype 52 oral thrush 52 Erythropoietic therapies may 52 Cardiotoxicity 52 smoldering myeloma 52 malarial infections 52 intrapartum 52 Neisseria 52 noninfectious 52 predisposing factors 52 MRSA bloodstream infection 52 Herpes Simplex Virus 52 Anaplasmosis 52 valent pneumococcal conjugate vaccine 52 Kaposi sarcoma 52 Candida species 52 orchitis 52 containing abacavir 52 HBV genotype 52 Allergic Rhinitis 52 Cotrimoxazole 52 Mitomycin C 52 ARIs 52 de ath 52 C. diff infections 52 Antiretroviral Therapy 52 abnormal cytology 52 Short Course DOTS 52 primaquine 52 Intermittent Preventive Treatment 52 Related Cancers 52 diarrhea scabies 52 chickenpox varicella 52 Streptococcal 52 oxacillin 52 Enterobacter cloacae 52 H. influenzae 52 Hepatotoxicity 52 pyrazinamide 52 monogenic 52 leukemia AML 52 Gatifloxacin 52 Antiretrovirals 52 Cerebral malaria 51 fosamprenavir 51 HPV Human Papillomavirus 51 Anti retroviral therapy 51 cytopenia 51 imipenem 51 Diabetic Neuropathy 51 chronic HCV 51 H pylori 51 LTBI 51 dengue viruses 51 hypereosinophilic syndrome 51 anogenital warts 51 genital lesions 51 choriocarcinoma 51 invasive MRSA infections 51 Plasmodium vivax 51 chronic eosinophilic leukemia 51 recurrent VTE 51 tipranavir ritonavir 51 immunocompetent patients 51 herpes zoster shingles 51 vaccine Menveo 51 myocardial infarctions MIs 51 Acute Myeloid Leukaemia AML 51 nosocomial 51 HBeAg positive 51 Trypanosomiasis 51 HIVAIDS 51 virologic breakthrough 51 enterocolitis 51 ZYVOX 51 relapsed AML 51 Fabry Disease 51 PLWH 51 ara C 51 HCV infection 51 pneumococcal infections 51 bacteriuria 51 Non Alcoholic Steatohepatitis 51 Rotavirus Vaccine 51 Diabetic Peripheral Neuropathy 51 TUBERCULOSIS 51 Chronic Renal Failure 51 mediastinitis 51 cancerdefine 51 chancroid 51 Plasmodium Falciparum 51 fungal meningitis 51 Streptococcus pneumoniae Haemophilus influenzae 51 Postoperative complications 51 Dengue Hemorrhagic Fever 51 aldosterone antagonists 51 dengue chikungunya 51 Rheumatoid 51 HBV infection 51 neutrophil counts 51 nevirapine Viramune 51 diphtheria pertussis whooping cough 51 nasal polyposis 51 Actinic Keratosis 51 Dengue hemorrhagic fever 51 Chronic hepatitis C 51 latent TB infection 51 darunavir 51 Skin rashes 51 murine leukemia virus 51 replicon 51 C trachomatis 51 DermaVir Patch 51 CCR5 antagonist 51 reemerging infectious diseases 51 biologic DMARD 51 Salmonella Typhi 51 Nosocomial pneumonia 51 Amgen Neulasta R 51 Cholangiocarcinoma 51 hereditary predisposition 51 BI/NAP#/# 51 leukaemias 51 chikungunya fever 51 atopic 51 Infected Patients 51 Chlamydia infection 51 nonvaccine serotypes 51 latently infected 51 GABHS 51 Ebola hemorrhagic fever 51 pneumocystis carinii pneumonia 51 Visceral leishmaniasis 51 Keratitis 51 malignant pleural mesothelioma 51 Dengue Haemorrhagic Fever 51 IgM antibodies 51 Staphylococcal 51 decompensated liver disease 51 aphthous ulcers 51 Severe Primary IGFD 51 haemolytic anemia 51 antiandrogens 51 INVANZ 51 CANCIDAS 51 Subgroup analyzes 51 quadrivalent vaccine 51 Cryptococcus neoformans 51 virological response 51 thrombotic events 51 cephalosporin antibiotics 51 antibiotic regimens 51 multidrug resistant organisms 51 stavudine d4T 51 Linezolid 51 perinatally 51 venous thromboembolic disease 51 serogroup B 51 superbug Clostridium difficile 51 mucormycosis 51 gastric stomach ulcers 51 acromegalic patients 51 tropism testing 51 Drug resistant strains 51 Clindamycin 51 melioidosis 51 TREATMENT OPTIONS 51 #:#-# [031] 51 PPSV# 51 metastatic malignant melanoma 51 aged ≥ 51 MDR strains 51 VRSA 51 Chlamydia pneumoniae 51 pegylated IFN 51 clinically evaluable 51 antiandrogen 51 protease inhibitors PIs 51 Tuberculosis MDR TB 51 vulvovaginal candidiasis 51 staphylococcal infections 51 neonatal sepsis 51 attending antenatal clinics 51 lopinavir ritonavir Kaletra 51 resistant organisms 51 Haemophilus influenzae 51 multidrug resistant 51 colorectal adenoma 51 lamivudine resistant 51 metastatic malignant 51 immunodeficiency 51 Entry Inhibitor 51 elevated triglyceride levels 51 keloid formation 51 chronic HCV genotype 51 intestinal metaplasia 51 CCR5 tropic HIV 51 HBeAg seroconversion 51 log# reduction 51 indinavir 51 HPV-#/# 51 K. pneumoniae 51 Pafuramidine 51 Catheter Associated 51 chlamydia gonorrhea syphilis 51 AVONEX ® 51 mycophenolate 51 Viral Load 51 CD8 responses 51 Necrotizing fasciitis 51 myocardial infarctions 51 posterior uveitis 51 seroprevalence 51 S. aureus strains 51 Panton Valentine leukocidin PVL 51 TNBC 51 BPS IC 51 protease inhibitor PI 51 paramyxoviruses 51 HPAI H#N# 51 Hepatitis E 51 Sexually transmitted infections STIs 51 carbapenem 51 Falciparum malaria 51 Polymorphisms 51 Mycobacterium avium complex 50 Waldenstrom macroglobulinemia 50 Enteric 50 β blockers 50 viral hemorrhagic fevers 50 uncomplicated falciparum malaria 50 Epstein Barr Virus 50 ART antiretroviral therapy 50 arterial thromboembolic 50 microscopic hematuria 50 lipohypertrophy 50 RhD negative 50 metastatic neuroendocrine tumors 50 Bcr Abl mutations 50 variola 50 chikungunya virus 50 leucopenia 50 nonvaccine 50 recurrent UTI 50 polysaccharide vaccines 50 systemic lupus erythematosus psoriasis 50 Chronic Kidney 50 clade C 50 Chronic Myeloid Leukemia 50 Non Hodgkin 50 treatment naïve genotype 50 PegIFN RBV 50 herpes encephalitis 50 HI Virus 50 Flavivirus 50 visceral leishmaniasis VL 50 midge borne 50 polymyxin B 50 diphtheria whooping cough tetanus 50 viral haemorrhagic fever 50 cardio vascular diseases 50 recurrent glioma 50 genital ulcer disease 50 Vaccine Candidate 50 boosted protease inhibitor 50 invasive pneumococcal diseases 50 Phenylketonuria PKU 50 Prolongs Survival 50 arterial thromboembolic events 50 Human papillomavirus HPV 50 Pneumococcal Conjugate Vaccine 50 serogroup C 50 Etravirine 50 Extensively Drug Resistant Tuberculosis 50 Human immunodeficiency virus 50 pyridostigmine 50 Klebsiella pneumonia 50 Lapdap 50 virologic failures 50 Allogeneic 50 Fixed Dose Combinations 50 Cloretazine 50 C. difficile infection 50 polytherapy 50 Chronic Hepatitis B 50 Epstein Barr Virus EBV 50 Alemtuzumab 50 HPV subtypes 50 Cutaneous T 50 AA Amyloidosis 50 INVEGA ® 50 CVD mortality 50 Systemic Sclerosis 50 immunosuppressed 50 Acute watery diarrhea 50 nucleotide analogue 50 Human Immuno deficiency 50 severely immunocompromised 50 serum urate levels 50 Valvular heart 50 human African trypanosomiasis 50 Haemophilus 50 chronic hepatitis 50 Clostridium difficile C. difficile 50 HCV infected 50 relapsed leukemia 50 Schistosomiasis 50 nadolol 50 rhinovirus infections 50 suppressive therapy 50 palivizumab 50 nonmelanoma skin cancer 50 methicillin resistant staph aureus 50 Celsentri Selzentry 50 SIV infection 50 resistant isolates 50 viral fevers 50 Vesivirus 50 transfusion transmitted 50 tenofovir Viread 50 TroVax ® 50 antifungal medications 50 GG genotype 50 pharyngeal cancer 50 ESBL producing 50 Isentress raltegravir 50 dengue leptospirosis 50 HCV genotype 50 NNRTI resistant virus 50 diarrhea cholera 50 Entamoeba histolytica 50 Iron Overload 50 Chronic Fatigue Syndrome CFS 50 Mucositis 50 Beta lactamase 50 cefotaxime 50 MenB 50 Diarrhoea 50 tick borne infections 50 Sleep Disordered Breathing 50 HEPATITIS C 50 % CI #.#-#.# [008] 50 MRSA bacteraemia 50 INFECTED WITH 50 CHIKV 50 node metastases 50 malarial parasites 50 M#V mutation 50 Plaquenil 50 vitamin D inadequacy 50 prolonged QT interval 50 Protease inhibitor 50 ethambutol 50 Respiratory syncytial virus RSV 50 quinolone antibiotics 50 MYCAMINE 50 Human papilloma virus 50 Heavy menstrual bleeding 50 cervical lesions 50 USA# strain 50 proguanil 50 Resistant Staphylococcus Aureus 50 Newly Diagnosed Multiple Myeloma 50 aeruginosa 50 VIRAMUNE R 50 B Cell Lymphoma 50 fibrosis progression 50 Chronic HCV 50 HBV HCV 50 hemorrhagic complications 50 immunomodulatory properties 50 serogroup 50 heavily pretreated 50 predisposing factor 50 darunavir r 50 alcoholic liver 50 poliovirus vaccine 50 plasmodium vivax 50 Human Papillomavirus 50 sero positive 50 Salmonella spp 50 ARV therapy 50 P falciparum 50 Acute Leukaemia 50 V. vulnificus 50 antithrombotic agent 50 H5 N1 50 Japanese encephalitis JE 50 C diff infections 50 Hospital Acquired Infections 50 artemether lumefantrine 50 TB bacillus 50 Adjuvant Treatment 50 Endocarditis 50 gemifloxacin 50 virulent diarrheal disease 50 pneumococcal carriage 50 relapsing remitting MS RRMS 50 TYGACIL 50 Lepto 50 C. jejuni 50 HIV Infection 50 coagulase negative staphylococci 50 Pharmacokinetics PK 50 dosage regimens 50 thromboprophylaxis 50 polycythemia vera essential thrombocythemia 50 LYSTEDA 50 perinatal mortality 50 Zidovudine 50 Amgen Neulasta ® 50 Cethromycin 50 nelfinavir 50 Sexually transmitted infections 50 Aptivus ® 50 genotype 1b 50 pseudomembranous colitis 50 haemolytic uraemic syndrome 50 serogroups 50 CIN2 + 50 cirrhotic 50 PLWAs 50 Maribavir 50 Polymorphic Ventricular Tachycardia CPVT 50 antiviral therapy 50 IOP lowering 50 H. Pylori 50 C. Difficile 50 QT interval prolongation 50 thyrotropin levels 50 antibody titers 50 LB# [003] 50 Haemorrhage 50 Hib disease 50 swine dysentery 50 heterosexually acquired 50 Staphylococcus aureus MSSA 50 oropharyngeal candidiasis 50 Sustiva efavirenz 50 diarrheal 50 Vacc 4x 50 COPD exacerbation 50 transcriptase inhibitors NNRTIs 50 NAbs 50 Genital herpes 50 Mycobacterium 50 Pseudomonas aeruginosa infections 50 Twinrix 50 Hydroxyurea 50 Glioblastoma Multiforme GBM 50 S. pyogenes 50 Prophylaxis 50 gastrointestinal stromal tumors GISTs 50 smoldering multiple myeloma 50 hematological parameters 50 virologic suppression 50 Aeromonas 50 imatinib resistance 50 MYH9 gene 50 baumannii 50 % CI #.#-#.# [003] 50 Helicobacter Pylori 50 virologically 50 Chronic Hepatitis C 50 colorectal carcinoma 50 hypoglycaemic episodes 50 Rimantadine 50 IgG4 50 meningococcal vaccines 50 Serotype 50 quinacrine 50 Anaemia 50 lipid lowering medications 50 sero prevalence 50 Resistant TB 50 diarrheal deaths 50 Vaccine Protects Against 50 C diff infection 50 Cell Lymphoma CTCL 50 Malnourishment 50 viral titers 50 AAT deficiency 50 certolizumab 50 bOPV 49 urolithiasis 49 Combination therapy 49 Onychomycosis 49 Haemorrhagic 49 thromboembolic disease 49 tetanus measles 49 Antiretroviral drugs 49 L. pneumophila 49 methicillin resistant MRSA 49 leukemia aplastic anemia 49 malaria endemic areas 49 HCV Hepatitis C 49 African trypanosomiasis 49 incidence ≥ 49 neurocognitive deficits 49 HPTN 49 Respiratory Virus 49 atopic disorders 49 pulmonary tuberculosis 49 events ADEs 49 Helicobacter pylori infection 49 Combination Therapies 49 antimicrobial prophylaxis 49 hemorrhagic fever viruses 49 herpes zoster virus 49 creatinine ratio 49 Incidences 49 Altastaph 49 Respiratory Syncytial Virus 49 Streptococci 49 lenalidomide dexamethasone 49 Virus Infection 49 spore forming bacterium 49 polysaccharide vaccine 49 HIV sero 49 #OHD 49 ACE Inhibitors 49 Gastro enteritis 49 HIV seronegative 49 Sexually Transmitted Diseases STDs 49 enterotoxigenic E. coli 49 Metastatic Prostate Cancer 49 acyclovir Zovirax 49 HCV Protease Inhibitor

Back to home page